Description
Nandrolone Decanoate
Strength: 250mg/ml
Molecular Formula: C28H44O3
Molecular Weight: 428.64716 g/mol
Active Ingredient: Nandrolone decanoate
CAS number: 360-70-3
Dosage Form: Injectable, oil base sterile solution
Route: Injection
Market Status: Prescription
Company: Hilma Biocare
DESCRIPTION
Nandrolone Decanoate 250 is an injectable anabolic preparation containing a short- acting
and a long-acting nandrolone ester. The short- acting phenylpropionate ester provides a
rapid increase in serum nandrolone levels followed by a long-acting enanthate ester with a
duration of action of 5 to 8 days. Nandrolone Decanoate 250 has the advantage of faster
onset than the traditional nandrolone decanoate and faster clearance. Nandrolone
Decanoate 250 accelerates muscle growth, stimulates appetite, increases red blood cell
production, and improves bone density.
CLINICAL PHARMACOLOGY
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and
adverse reactions demonstrate the androgenic properties of these drugs. Complete
dissociation of anabolic and androgenic effects has not been achieved. The actions of
anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release
is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback inhibition of pituitary folliclestimulating hormone (FSH). Nandrolone Decanoate 250 is a sex steroid derivative with
anabolic, androgenic, and progestin based activity. Nandrolone binds to androgen receptors
increasing nitrogen retention and increasing protein synthesis in muscle cells resulting in
increased strength and growth of muscle tissue. Some nandrolone metabolic byproducts are
suspected to act as synthetic progestins which may explain the subjective claims of joint
comfort reported With nandrolone use. Nandrolone is subject to hepatic metabolism.
INDICATIONS
Osteoporosis due to androgen deficiency in hypogonadal males. Treatment of anemia in
cases of renal insufficiency where oxymetholone is contraindicated Restoration of muscle
mass in patients with muscular atrophy after traumatic recovery.
ADVERSE REACTIONS
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages:Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances Retention of sodium, chloride, water, potassium, calcium, and
inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely,
hepatocellular neoplasms,es peliosis hepatis, hepatic lerer adenomas, and cholestatic
hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & x bleeding in patients on anti.
coagulant therapy.
Nervous System: Increased or decreased libido, headache. anxiety, depression, and
generalized paresthesia.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and
potentiation of sleep apnea.
CONTRAINDICATIONS
Not for use in women or children. Patients with known hypersensitivity to any ingredients in
this product. Patients with known or suspected prostatic, testicular, hepatic, or mammary
carcinoma. Patients with nephrosis or the nephrotic phase of nephritis, hypercalcaemia,
oedema, jaundice, or liver or kidney disease with impaired bilirubin excretion. Products
containing androgens should not be used in women as they may cause virilization and fetal
harm. Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine or
a history of these conditions, since anabolic steroids may induce salt and fluid retention.
PRECAUTIONS
Because androgens may alter serum cholesterol concentration, caution should be used
when administering these drugs to patients with a history or myocardial infarction or
coronary artery disease. Patients on oral anticoagulant therapy require close monitoring
especially when androgens are started or stopped. Diabetics: androgens may alter the
metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with
diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic
drugs.
DRUG INTERACTIONS
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which
may require adjustment of dosage. Anticoagulants: Patients on anticoagulants should be
carefully monitored during anabolic steroid therapy as anabolic steroids may increase
sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic
steroid therapy, particularly during initiation and termination of therapy.
PATIENT MONITORING
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT. Prostatic specific antigen- PSA, Testosterone: total, free, and bioavailable.
Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate
should continue while on androgen therapy, especially in patients with difficulty in urination
or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 150 – 300 mg injected IM every 5 – 7 days for a duration of 8 to 12 weeks.
PRESENTATION
Nandrolone Decanoate 250 mg/ml, 10ml multiple dose vial.
STORAGE
Store in a cool dry place between 15 – 25°C. Protect from light.
Reviews
There are no reviews yet.